Olanzapine‐Associated Diabetes Mellitus

  title={Olanzapine‐Associated Diabetes Mellitus},
  author={Elizabeth A. Koller and P. Murali Doraiswamy},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  • E. Koller, P. Doraiswamy
  • Published 1 July 2002
  • Medicine, Psychology
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Study Objective. To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine. 

Further Evidence of Olanzapine-Associated Diabetes

The clinical characteristics of hyperglycemia in patients treated with olanzapine are identified and these researchers identified 237 cases of hyper glycemia.

Risperidone‐Associated Diabetes Mellitus: A Pharmacovigilance Study

The objective is to explore the clinical characteristics of hyperglycemia in patients treated with risperidone and to find out whether these characteristics can be improved with further treatment.

Antipsychotic drugs and risk of type 2 diabetes: An evidence‐based approach

To review studies conducted to evaluate the risk of type 2 diabetes in patients treated with different antipsychotic drugs (AP), six studies were conducted in the Netherlands over a 10-year period.

Ziprasidone as an adjuvant for clozapine‐ or olanzapine‐associated medical morbidity in chronic schizophrenia

This study sought to examine the effect of ziprasidone on olanzapine or clozapine‐associated medical morbidity such as insulin resistance, diabetes mellitus (DM) and impaired fasting glucose,

Metabolic Syndrome and Oxidative Stress in Ghanaian Psychiatric Patients: Conventional Vs. Atypical Antipsychotic Medications

A Thesis Submitted in Fulfillment of the Requirements for the Degree of Master of Philosophy in the Department of Molecular Medicine, School of Medical Sciences, 2010 about the role of nanofiltration in the response to infectious disease.

Comparative Study of the Development of Diabetes Mellitus in Patients Taking Risperidone and Olanzapine

Differences in risk of developing diabetes mellitus during treatment with olanzapine and risperidone are assessed by using patients treated with haloperidol and fluphenazine as control subjects in whom the authors would not expect to see an increased risk.

Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children

Objectives:  To estimate the frequency of neuropsychiatric disease (NPD) in an urban pediatric type 2 diabetes mellitus (T2DM) population, to compare demographic characteristics of affected patients

Hyperglycemia associated with olanzapine treatment

The authors report a series of diabetes associated with olanzapine treatment from Indian context and the clinical implications this emerging side effect is discussed.

Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.

Patients with schizophrenia have increased rates of morbidity and mortality due primarily to cardiovascular disease, compared with the general population, and the possibility that some antipsychotic drugs add to this increased risk, likely due to drug-induced weight gain and associated metabolic abnormalities including hyperglycemia, diabetes mellitus, and dyslipidemia.

Pancreatitis Associated with Atypical Antipsychotics: From the Food and Drug Administration's MedWatch Surveillance System and Published Reports

Study Objective. To investigate the relative numbers and clinical characteristics of pancreatitis in patients treated with the atypical antipsychotic agents, clozapine, olanzapine, and risperidone,



Weight gain during treatment with valproate

An analysis was made of weight changes during treatment with valproate in 63 adult epileptic patients and the results confirmed that weight loss is associated with disease progression.

Diabetes as a result of atypical anti‐psychotic drugs – a report of three cases

  • V. RigalleauB. Gatta H. Gin
  • Medicine, Psychology
    Diabetic medicine : a journal of the British Diabetic Association
  • 2000
Aims  Atypical anti‐psychotic drugs (APDs) are widely used in psychotic disorders refractory to conventional neuroleptic agents.

Diabetic ketoacidosis associated with olanzapine in an adolescent patient.

A case of acute onset diabetic ketoacidosis presenting in a 16-year-old girl during olanzapine therapy is reported, reported until now only in adults.

Olanzapine-Induced Diabetes Mellitus

Reports of new-onset diabetes due to olanzapine are consistent with those in the literature and certain risk factors such as obesity, family history, and concomitant medications may predispose an individual to development of diabetes mellitus while taking olanZapine.

Olanzapine-Induced Diabetic Ketoacidosis

Clinicians should monitor blood glucose concentrations periodically in patients taking olanzapine, especially in those patients with risk factors for diabetes mellitus, especially after a 46-year-old African American woman who developed diabetic ketoacidosis was diagnosed with DKA and acute pancreatitis.

Olanzapine-Induced Glucose Dysregulation

Olanzapine has shown greater clinical efficacy and is associated with fewer extrapyramidal side effects than typical antipsychotics, it may produce exacerbation or new emergence of diabetes mellitus, and further examination of the incidence and etiology of glucose dysregulation after the initiation of olanZapine therapy is necessary.

Olanzapine‐Associated Severe Hyperglycemia, Ketonuria, and Acidosis: Case Report and Review of Literature

A 27-year-old African‐American man developed new‐onset severe hyperglycemia, with ketonuria and acidosis, but no weight gain, 2 years after starting olanzapine, although his diabetes was stabilized with insulin, his family had difficulty monitoring his therapy, and insulin was discontinued.

Olanzapine-Induced Hyperglycemic Nonketonic Coma

It appears that olanzapine caused hyperglycemia by a mechanism other than weight gain in this patient, and others from the literature suggest that oanzapine therapy may induce hyper glycemia in some patients.

Hyperglykämie und Ketoazidose unter Olanzapin

Two psychotic patients developed hyperglycaemia several weeks after starting olanzapine, and in the second case severe ketoacidosis with letal outcome occured.

Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.

It is suggested that the dose of antidepressant medication that leads to a satisfactory acute therapeutic response should be maintained during long-term treatment to prevent relapse or recurrence of depression.